Sesja plenarna I<br>New drugs in systemic sclerosis

Lidia Rudnicka; Justyna Sicińska

eISSN: 2084-9893
ISSN: 0033-2526

Dermatology Review/Przegląd Dermatologiczny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

2/2009
vol. 96

Send email

Copy url:

abstract:

Sesja plenarna I
New drugs in systemic sclerosis

Lidia Rudnicka

,

Justyna Sicińska

Przegl Dermatol 2009, 96, 85–89

Online publish date: 2009/04/30

View full text Get citation

In recent years opinions about treatment of systemic sclerosis (SSc) have undergone significant evolution. Currently, drugs which improve microcirculation are considered the treatment of choice in patients with mild disease. The only immunosuppressive drug with confirmed efficacy in reducing cutaneous and pulmonary changes in SSc remains cyclophosphamide. A significant breakthrough was introduction of bosentan as well as an effective, off-label application of mycophenolate mofetil and sildenafil in patients with SSc. Biological therapy with rituximab or other antilymphocyte B recombinant proteins, might develop into the future treatment of systemic sclerosis.

keywords:

Sesja plenarna INew drugs in systemic sclerosis

Lidia Rudnicka , Justyna Sicińska

drugs, systemic sclerosis

Sesja plenarna I
New drugs in systemic sclerosis

Lidia Rudnicka

,

Justyna Sicińska